Hypertension augmented COVID-19 through renin-induced internalization of platelet-ACE2 / SARS-Cov-2 complexes
Hypertension augmented COVID-19 through renin-induced internalization of platelet-ACE2 / SARS-Cov-2 complexes
批准号:
10490385
负责人:
Thomas M McIntyre
金额:
$57.23万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-20 至 2025-08-31
关键词:
2019-nCoVACE2AcuteAffinityAgeAgonistAldosteroneAngiotensinogenAnimalsAutopsyBindingBloodBlood CirculationBlood Coagulation DisordersBlood PlateletsBlood coagulationBlood-Air BarrierCOVID-19COVID-19 pandemicCOVID-19 patientCOVID-19 prognosisCOVID-19 riskCardiovascular systemCellsClosure by clampCoagulation ProcessComplexConsumptionDenervationDepositionDiseaseEatingEndothelial CellsEndotheliumEssential HypertensionF2R geneFDA approvedFactor XaFibrinFibrinolytic AgentsFibrosisFunctional disorderGeneticGerman populationHeart InjuriesHumanHypertensionInactive ReninIncidenceInfectionInflammationKidneyLentivirusLiverLungLung diseasesMass Spectrum AnalysisMeasuresMediatingMegakaryocytesMembraneMusNervous System TraumaOrganOutcomePathway interactionsPatientsPatternPepstatinsPeptide HydrolasesPharmaceutical PreparationsPhosphatidylserinesPlasmaPlatelet ActivationPlatelet aggregationProteinsProteolysisPulmonary alveolar structureRNARattusReninReporterReticuloendothelial SystemRiskRisk FactorsRoleRouteSARS-CoV-2 infectionSARS-CoV-2 spike proteinSevere Acute Respiratory SyndromeSignal TransductionSiteSpleenSurfaceSystemTMPRSS2 geneTestingTherapeuticThrombinThrombin ReceptorThrombocytopeniaThromboembolismThromboplastinThrombosisThrombusTissuesTransgenic AnimalsTransgenic OrganismsTropismViralVirusaliskirencell injurycomorbidityfactor IXa-factor VIIIaheart damagehypertensivein vivoinhibitorinnovationliver injurylung injurymacrophagemultiorgan damagenovelnovel strategiesparticleprophylacticprorenin receptorprotein complexreceptorrenal damagerespiratorythromboticthrombotic complicationsuptakevector
中文摘要
由于未知原因,高血压是导致COVID-19预后不良的主要合并症风险因素。非典,
英文摘要
Hypertension, for unknown reasons, is a primary co-morbidity risk factor for poor COVID-19 outcomes. SARS-
Cov-2 breaches the lung blood-air barrier to spread among organs inducing endothelial cell dysfunction and
multi-organ thromboembolism. ACE2 is the high affinity receptor for SARS-Cov-2 with TMPRSS2 cleavage then
enabling fusion. However, ACE2 and TMPRSS are not co-expressed by all SARS-Cov-2 infected organs.
We discovered human platelets express ACE2 and TMPRSS, bind SARS-Cov-2 spike protein, and
internalize ACE2-spike protein complexes. SARS-Cov-2 RNA accumulates within platelets.
Platelets are activated in essential hypertension, transgenic renin expression stimulates fibrosis and
coagulation, and inhibition of coagulation blocks renin fibrosis. The direct renin inhibitor Aliskiren blocks
thrombosis in hypertensive animals, so renin intercalates into coagulation to initiate thromboembolic disease.
We discovered cells releasing prorenin stimulate explosive platelet activation, but in a unique way; the onset
of activation was very delayed, and activation was always maximal. Mechanistically, prorenin interacted with
quiescent platelets promoting escape of intracellular phosphatidylserine onto the platelet surface.
Phosphatidylserine organizes tenase and prothrombinase coagulation complexes, forming factor Xa and then
thrombin that explosively activated the platelet PAR1 thrombin receptor. Aliskiren abolished phosphatidylserine
expression, thrombin formation, and thrombosis. This establishes renin as a novel, direct platelet agonist.
Platelets displaying surface phosphatidylserine are rapidly cleared by engulfment by endothelial cells and
perivascular macrophages of the reticuloendothelial system of liver, lung, and spleen. We postulate
hypertension and renin expression promotes phosphatidylserine display on platelets, initiating coagulation and
platelet activation, but also promoting rapid platelet clearance. This, we postulate, internalizes SARS-Cov-2 into
cells that need not express ACE2 or TMPRSS2, themselves.
Aim 1. Test the hypothesis that renin-activated platelets are entry vectors for SARS-Cov-2 into
endothelial cells and macrophages of the reticuloendothelial system.
Aim 2. Test the hypothesis renin-stimulated platelet turnover in vivo introduces SARS-Cov-2
pseudotyped lentivirus-platelet complexes into diverse organs.
This project will establish a functional connection between hypertension and SARS-Cov-2 infection, identify
renin activated platelets as novel SARS-Cov-2 entry vectors, and define a basis for altered platelet clearance in
renin-clamped hypertensive mice. This provides a translational basis for Aliskiren use to normalize hypertension
risk in COVID-19, elucidates novel approaches to suppress SARS-Cov-2 organ infection and damage, and
establish circulating platelet ACE2 expression as a measure of risk for COVID-19 multi-organ damage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hypertension augmented COVID-19 through renin-induced internalization of platelet-ACE2 / SARS-Cov-2 complexes
-
批准号:10275251
-
项目类别:
-
资助金额:$57.23万
-
财政年份:2021
-
负责人:Thomas M McIntyre
-
依托单位:
Pilot Project Core
-
批准号:10397511
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2016
-
负责人:Thomas M McIntyre
-
依托单位:
Core D: Pilot Project Core
-
批准号:8977737
-
项目类别:
-
资助金额:$18.78万
-
财政年份:2016
-
负责人:Thomas M McIntyre
-
依托单位:
Pilot Project Core
-
批准号:10056026
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2016
-
负责人:Thomas M McIntyre
-
依托单位:
Pilot Project Core
-
批准号:10609546
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2016
-
负责人:Thomas M McIntyre
-
依托单位:
Dynamic regulation of thrombosis by the platelet proteome
-
批准号:9336334
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2016
-
负责人:Thomas M McIntyre
-
依托单位:
Systemic Oxidized Phospholipids in Mitochondrial Dysfunction of Alcoholic Injury
-
批准号:7671505
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2008
-
负责人:Thomas M McIntyre
-
依托单位:
Systemic Oxidized Phospholipids in Mitochondrial Dysfunction of Alcoholic Injury
-
批准号:7522644
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2008
-
负责人:Thomas M McIntyre
-
依托单位:
Systemic Oxidized Phospholipids in Mitochondrial Dysfunction of Alcoholic Injury
-
批准号:8318216
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2008
-
负责人:Thomas M McIntyre
-
依托单位:
Systemic Oxidized Phospholipids in Mitochondrial Dysfunction of Alcoholic Injury
-
批准号:8135614
-
项目类别:
-
资助金额:$39.04万
-
财政年份:2008
-
负责人:Thomas M McIntyre
-
依托单位:
Systemic Oxidized Phospholipids in Mitochondrial Dysfunction of Alcoholic Injury
-
批准号:7919248
-
项目类别:
-
资助金额:$39.54万
-
财政年份:2008
-
负责人:Thomas M McIntyre
-
依托单位:
CATABOLISM OF OXIDIZED PHOSPHOLIPIDS BY VASCULAR CELLS
-
批准号:7337246
-
项目类别:
-
资助金额:$39.04万
-
财政年份:2007
-
负责人:Thomas M McIntyre
-
依托单位:
Oxidized Phospholipids in Vascular Pathobiology
-
批准号:8101061
-
项目类别:
-
资助金额:$228.08万
-
财政年份:2007
-
负责人:Thomas M McIntyre
-
依托单位:
Circulating Age-related Lipid Mediators in Thrombosis
-
批准号:7340884
-
项目类别:
-
资助金额:$54.04万
-
财政年份:2007
-
负责人:Thomas M McIntyre
-
依托单位:
Circulating Age-related Lipid Mediators in Thrombosis
-
批准号:7664311
-
项目类别:
-
资助金额:$55.38万
-
财政年份:2007
-
负责人:Thomas M McIntyre
-
依托单位:
Circulating Age-related Lipid Mediators in Thrombosis
-
批准号:7896473
-
项目类别:
-
资助金额:$53.3万
-
财政年份:2007
-
负责人:Thomas M McIntyre
-
依托单位:
Leukocyte Responses to Endotoxin
-
批准号:6933885
-
项目类别:
-
资助金额:$28.92万
-
财政年份:2004
-
负责人:Thomas M McIntyre
-
依托单位:
Leukocyte Responses to Endotoxin
-
批准号:6771261
-
项目类别:
-
资助金额:$31.61万
-
财政年份:2004
-
负责人:Thomas M McIntyre
-
依托单位:
Endotoxin Generated Lipid Second Messengers
-
批准号:6826829
-
项目类别:
-
资助金额:$28.21万
-
财政年份:2002
-
负责人:Thomas M McIntyre
-
依托单位:
Endotoxin Generated Lipid Second Messengers
-
批准号:6574684
-
项目类别:
-
资助金额:$37.79万
-
财政年份:2002
-
负责人:Thomas M McIntyre
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: